Univ of Pittsburgh Medical Center Hillman Cancer Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Najjar, Yana M
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
NCT04493203 / 2005-001438-34: Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Active, not recruiting
2
31
US
Nivolumab, Opdivo, AG013736, Axitinib, INLYTA
Yana Najjar, Pfizer, Bristol-Myers Squibb
Advanced Melanoma, Unresectable Melanoma
04/24
02/29
NCT04511013: A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Recruiting
2
112
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
06/27
06/27
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
NCT06216938: RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting
1
25
US
Vusolimogene oderparepvec (RP1)
Yana Najjar, Replimune Inc.
Melanoma
01/26
07/28
ACTM-838-01, NCT06336148: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Recruiting
1
35
US, RoW
ACTM-838
Actym Therapeutics, Inc.
Solid Tumor
01/26
07/26
AIM-NIVO, NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Recruiting
1
300
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
08/26
08/26
STEALTH-001, NCT06444815: A Study of VET3-TGI in Patients With Solid Tumors

Recruiting
1
60
US
VET3-TGI, Pembrolizumab
KaliVir Immunotherapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
09/27
12/27
NCT03311308: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Recruiting
1
30
US
Pembrolizumab Injection [Keytruda], Keytruda, Metformin
Yana Najjar, Merck Sharp & Dohme LLC
Advanced Melanoma
01/27
12/28
NCT04658303: Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting
N/A
20
US
Pimonidazole
Yana Najjar
Melanoma
03/27
03/27
Rose, Amy
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT04493203 / 2005-001438-34: Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Active, not recruiting
2
31
US
Nivolumab, Opdivo, AG013736, Axitinib, INLYTA
Yana Najjar, Pfizer, Bristol-Myers Squibb
Advanced Melanoma, Unresectable Melanoma
04/24
02/29
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT04808999: Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Active, not recruiting
2
30
US
Pembrolizumab Injection, Keytura
Diwakar Davar, Merck Sharp & Dohme LLC
Squamous Cell Carcinoma
04/24
04/29
Neo-MEL-T, NCT04139902: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) Vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Recruiting
2
62
US
Dostarlimab (TSR-042) (singly), Dostarlimab, Dostarlimab (TSR-042) and TSR-022 (combination)
Diwakar Davar, Tesaro, Inc.
Melanoma Stage III, Melanoma Stage IV
09/25
04/29
NCT05130177: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Recruiting
2
26
US
Zimberelimab, AB122, Domvanalimab, AB154
Diwakar Davar, Arcus Biosciences, Inc.
Melanoma
01/27
01/30
FMT-ELIMINATE, NCT06499896: Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)

Recruiting
2
30
US
MTP-101-C
Diwakar Davar, Stanley Marks Fund for Cancer Research, Cures Within Reach
Immune-mediated Colitis (IMC), Immune-related Dermatitis
09/26
09/30
NCT06030037: Pembrolizumab/Lenvatinib with and Without Responder-derived FMT in Relapsed/Refractory Melanoma

Not yet recruiting
2
56
US
Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab, Lenvatinib
Diwakar Davar, Merck Sharp & Dohme LLC, Gateway for Cancer Research
PD-1 Refractory Advanced Melanoma
12/29
12/29
NCT05061017: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Completed
2
14
US
Pixatimod, (PG545), Nivolumab, OPDIVO®, Cyclophosphamide (low dose)
Diwakar Davar, Aculeus Therapeutics
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
02/24
03/24
NCT06070012: Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Not yet recruiting
2
44
US
Tebentafusp, Kimmtrak
Diwakar Davar, Immunocore Ltd
Uveal Melanoma
11/26
11/29
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
NCT04401995: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

Completed
2
9
US
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Diwakar Davar, Checkmate Pharmaceuticals, CellSight Technologies, Inc.
Melanoma
08/24
08/24
NCT05669846: Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC

Recruiting
2
26
US
Fecal Microbiota Transplant (FMT), Pembrolizumab, Keytruda
Diwakar Davar, Gateway for Cancer Research
Non Small Cell Lung Cancer
12/29
12/29
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
NCT04074967: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Checkmark Data in combination with nivolumab in high-risk, PDL1–refractory advanced solid tumors at SITC 2022
Nov 2022 - Nov 2022: Data in combination with nivolumab in high-risk, PDL1–refractory advanced solid tumors at SITC 2022
Active, not recruiting
1/2
70
US
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Jason J. Luke, MD, Array BioPharma
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
10/24
10/25
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
NCT06216938: RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting
1
25
US
Vusolimogene oderparepvec (RP1)
Yana Najjar, Replimune Inc.
Melanoma
01/26
07/28
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
NCT04572451: Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Recruiting
1
50
US
nivolumab, Opdivo®, Anti-PD-1, BMS-986253, Anti-IL-8, Stereotactic Body Radiotherapy (SBRT)
Jason J. Luke, MD, Bristol-Myers Squibb
Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
05/24
05/27
NCT03311308: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Recruiting
1
30
US
Pembrolizumab Injection [Keytruda], Keytruda, Metformin
Yana Najjar, Merck Sharp & Dohme LLC
Advanced Melanoma
01/27
12/28
NCT06599619: Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting
N/A
30
US
Nivolumab, OPDIVO®, Pembrolizumab, Keytruda
John Kirkwood, Melanoma Research Foundation
Melanoma
12/25
12/25
NCT04658303: Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting
N/A
20
US
Pimonidazole
Yana Najjar
Melanoma
03/27
03/27

Download Options